Reactivation of HBV with Rituximab Rituximab, a chimeric mouse-human monoclonal antibody against CD20+ lymphocytes  CD20+ NHL; CLL; rheumatoid arthritis  Prolonged decrease in anti-HBs >7 months after last dose CLL, chronic lymphocytic leukemia.
{}